Skip to main content
    J

    Johnson & Johnson (JNJ)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $278.82
    -3.73 (-1.32%)

    Market Cap: $680.19B

    Last updated: Nov 17, 2026 at 4:43 PM ET

    Johnson & Johnson (JNJ) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Johnson & Johnson (JNJ) has a market cap of $680.19B and an enterprise value of $707.93B. Its trailing P/E of 26.2x is above its 10-year median of 17.1x.

    Total Valuation

    Enterprise value is 4.08% above the market cap, as debt exceeds cash.

    Market Cap$680.19B
    Enterprise Value$707.93B
    Latest price (Nov 17, 2026)$278.82

    Key Dates

    The next earnings report is set for Jan 26, 2027, after the close. The next ex-dividend date is Nov 24, 2026.

    Next Earnings DateJan 26, 2027, after the close
    Last Earnings DateOct 13, 2026
    Next Ex-Dividend DateNov 24, 2026
    Next Payment DateDec 8, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.09% in the quarter ended Sep 30, 2026 and grew 0.05% a year over 2 years.

    Shares Outstanding2.41B
    Shares Change (YoY)+0.05%
    Shares Change (QoQ)+0.09%
    Share Count Growth (2Y CAGR)+0.05%

    Valuation Ratios

    Sales and book value multiples are 6.8x and 8.2x. Its year-end P/E ranged from 14.5x to 19.6x from 2016 to 2025.

    P/E Ratio26.2x
    Forward P/E24.8x
    P/S Ratio6.8x
    Forward P/S6.7x
    P/B Ratio8.2x
    P/FCF Ratio33.6x
    P/OCF Ratio26.0x
    PEG Ratio2.6

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 27.0x EBITDA and 35.0x free cash flow.

    EV / Earnings44.0x
    EV / Sales7.1x
    EV / EBITDA27.0x
    EV / EBIT39.7x
    EV / FCF35.0x

    Price Statistics

    The stock is up 43.96% over 52 weeks and trades 4.35% above its 50-day average.

    Beta (1Y)-0.05
    52-Week Change+43.96%
    1-Month Change+9.86%
    3-Month Change+2.48%
    6-Month Change+22.53%
    5-Year Change+67.73%
    10-Year Change+135.54%
    Total Return (1Y)+46.68%
    Total Return (3Y CAGR)+25.61%
    Total Return (5Y CAGR)+14.07%
    Return vs SPY (1Y)+29.47%
    Max Drawdown (1Y)-11.39%
    Max Drawdown (3Y)-14.45%
    Sharpe Ratio (1Y)1.64
    Correlation with SPY (1Y)-0.03
    50-Day Average$267.20
    200-Day Average$249.11
    52-Week Range$194.99 to $290.25
    RSI (14 Days)56.6
    Average Volume (20 Days)7.44M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.02x current liabilities, and total debt is 0.55x shareholder equity.

    Current Ratio1.02x
    Quick Ratio0.74x
    Debt / Equity0.55x
    Debt / EBITDA1.72x
    Debt / FCF2.23x
    Interest Coverage18.14x

    Returns and Efficiency

    Return on invested capital is 12.84% over the last 12 months, against a 5-year average of 15.38%.

    Return on Equity (ROE)19.74%
    Return on Assets (ROA)8.15%
    Return on Invested Capital (ROIC)12.84%
    Return on Capital Employed (ROCE)12.57%
    ROE (5Y Average)31.04%
    ROA (5Y Average)12.66%
    ROIC (5Y Average)15.38%
    Asset Turnover0.51x
    Inventory Turnover2.11x
    Receivables Turnover5.22x
    Cash Conversion Cycle138 days

    Taxes

    Income tax took 9.26% of pretax income over the last 12 months.

    Income Tax (TTM)$1.64B
    Effective Tax Rate9.26%

    Scores

    JNJ has an Altman Z-Score of 5.48, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score5.48
    Altman Z ZoneSafe
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $99.33B over the last 12 months is up 7.80% from the 12 months before.

    Revenue$99.33B
    Revenue Growth (YoY)+7.80%
    Gross Profit$67.11B
    Operating Income$24.74B
    Pretax Income$17.74B
    Net Income$16.09B
    EBITDA$25.94B
    EBIT$17.85B
    Reported EPS (TTM)$10.65

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 41.30% of the $197.43B in total assets.

    Cash and Equivalents$16.91B
    Total Debt$44.65B
    Net Debt$27.74B
    Net Debt Per Share$11.51
    Working Capital$894.00M
    Shareholder Equity$81.53B
    Book Value Per Share$33.84
    Tangible Book Value-$13.60B
    Total Assets$197.43B
    Total Liabilities$115.90B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $6.18B of capital spending, operating cash flow left $19.98B of free cash flow.

    Operating Cash Flow$26.16B
    Capital Expenditures$6.18B
    Free Cash Flow$19.98B
    FCF Per Share$8.29
    Depreciation and Amortization$8.09B
    Dividends Paid$12.72B
    Share Repurchases$7.88B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 24.90%, against a 5-year average of 25.06%.

    Gross Margin67.56%
    Operating Margin24.90%
    Pretax Margin17.86%
    Net Margin16.20%
    EBITDA Margin26.11%
    EBIT Margin17.97%
    FCF Margin20.11%
    Gross Margin (5Y Average)69.06%
    Operating Margin (5Y Average)25.06%
    Net Margin (5Y Average)26.90%

    Growth

    Revenue grew 5.60% a year over 3 years, and EPS 2.06% a year.

    Revenue Growth (3Y CAGR)+5.60%
    Revenue Growth (5Y CAGR)+2.67%
    EPS Growth (3Y CAGR)+2.06%
    EPS Growth (5Y CAGR)+6.11%
    FCF Growth (3Y CAGR)+4.65%
    FCF Growth (5Y CAGR)-0.49%
    Operating Income Growth (3Y CAGR)+8.21%
    Book Value Per Share Growth (2Y CAGR)+8.70%

    Revenue and profit by year

    Dividends and Yields

    JNJ pays out 48.64% of earnings as dividends.

    Dividend Per Share (Annual)$5.36
    Dividend Yield1.92%
    Payment ScheduleQuarterly
    Dividend Growth (3Y CAGR)+4.92%
    Dividend Growth (5Y CAGR)+5.25%
    Payout Ratio48.64%
    FCF Payout Ratio63.64%
    Earnings Yield3.82%
    FCF Yield2.97%
    Buyback Yield1.17%
    Shareholder Yield3.07%

    Full dividend history

    Stock Splits

    The last split was a 2-for-1 forward split on Jun 13, 2001.

    Last Split DateJun 13, 2001
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 9 similar companies, JNJ has the 3rd highest P/E.

    P/E Ratio26.2x vs 19.8x median
    P/S Ratio6.8x vs 4.9x median
    ROIC12.84% vs 13.95% median
    Revenue Growth (Trailing 4 Quarters, YoY)+7.80% vs +6.13% median
    Dividend Yield1.92% vs 2.69% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 6.96% and EPS growth at 3.74% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+6.96%
    EPS Growth Forecast (2Y CAGR)+3.74%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About JNJ

    What is JNJ's market cap?

    Johnson & Johnson has a market cap of $680.19B. Its enterprise value, which adds debt and subtracts cash, is $707.93B.

    What is JNJ's P/E ratio?

    Johnson & Johnson has a trailing P/E ratio of 26.2x and a forward P/E of 24.8x.

    How many shares of JNJ are outstanding?

    Johnson & Johnson has 2.41B shares outstanding. The count is up 0.05% from a year earlier.

    Does JNJ pay a dividend?

    Yes. Johnson & Johnson pays $5.36 a share a year, a dividend yield of 1.92%.

    How much debt does JNJ have?

    Johnson & Johnson has $44.65B of total debt and $16.91B of cash and equivalents, a net debt position of $27.74B.